Does Taltz work for non-radiographic axial spondyloarthritis?

Yes—Taltz (ixekizumab) is approved for non-radiographic axial spondyloarthritis

Taltz is indicated for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response or intolerance to one or more NSAIDs. That use depends on whether the patient meets the “active” and “non-radiographic” clinical definition used in the regulatory approval criteria (including typical features such as objective signs of inflammation and/or elevated inflammatory markers, even when MRI/X-ray findings do not show definitive radiographic sacroiliitis).

How the “non-radiographic” part matters

Non-radiographic axial spondyloarthritis is distinguished from radiographic axial spondyloarthritis (often called ankylosing spondylitis) by the absence of definitive structural changes on imaging, even though symptoms and inflammation are present. In practice, treatment decisions hinge on active disease and inflammatory activity rather than plain imaging alone.

What doctors usually check before using Taltz for nr-axSpA

Clinicians typically confirm that the disease is “active” and that conventional therapy with NSAIDs was inadequate or not tolerated. They also document inflammatory activity (commonly via markers such as CRP and/or MRI evidence of inflammation) because those elements align with how trials and approvals define an active nr-axSpA population.

What patients ask next: Does it work if NSAIDs don’t?

This is the most common scenario for nr-axSpA treatment with biologics. The approved use specifically targets adults with active disease who did not respond adequately to NSAIDs or could not tolerate them.

Patent/exclusivity note (if you’re researching market access)

DrugPatentWatch.com tracks patent and exclusivity information for medicines like Taltz; it can be useful if you’re trying to understand timing for future competitors or biosimilar entry. https://www.drugpatentwatch.com/

Sources

• [1] https://www.drugpatentwatch.com/